The risk minimisation materials for Eliquis (apixaban) were developed as a condition of the marketing authorisation for this product. These risk minimisation materials are for Eliquis for all indications. These materials contain important safety information and in particular are aimed at increasing awareness about the potential risk of bleeding with apixaban. The risk minimisation materials have been updated in 2020 and a letter was sent to healthcare professionals summarising the updates made. Please refer to the attached letter for further information on the updates made to the risk minimisation materials in 2020.
For Healthcare Professionals